Acute Pain Clinical Trial
Official title:
Clinical Evaluation of Penthrox (Methoxyflurane)and Tramadol for the Singapore Emergency Ambulance Service
Introduction
Current practice in Singapore Emergency Ambulance Service (EAS) includes the use of
analgesia delivered via inhalation Enthanox (Nitrous Oxide). However there are difficulties
administering Enthanox on-scene due to the added weight of carrying bulky cylinder tanks. It
is common for a delay in administration of analgesia. Inhaled methoxyflurane (Penthrox) is a
potential agent for early administration of analgesia by Singapore Civil Defense Force
(SCDF) EAS. It is extensively used in the pre-hospital setting in Australia. However data on
its use as an analgesic agent in general are limited and there are few published controlled
trials of methoxyflurane in an analgesic role. Intramuscular (IM) tramadol is a common
medication used in the hospital setting for analgesia. It is well proven, simple to deliver
and is not a controlled drug.
Aim
To compare Penthrox and Tramadol in the treatment of acute pain in patients transported by
the SCDF EAS.
Methodology
The trial will recruit 400 eligible patients over 1 year (200 Penthrox and 200 tramadol).
Patients managed by SCDF EAS for treatment of acute pain and who meet the eligibility
criteria will be recruited into the study. Half of SCDF's 30 ambulances (15 ambulances),
will be randomly assigned, equipped and trained to carry the new medication (Penthrox). The
other half (15 ambulances), will be trained and equipped with tramadol. Allocation will be
on a per station level. After 6 months, they will cross over to Penthrox and tramadol
respectively.
All paramedics will be trained to use both medications, pain scales and Ramsey scores, and
will record patient's pain, sedation scores and patient satisfaction as part of routine
clinical practice. All patients will be followed up by a review of their Emergency
Department and hospital records for any medication related adverse effects.
Hypothesis
The investigators hypothesize that in patients with acute pain (pain score ≥3), presenting
to the ambulance service with musculo-skeletal trauma (limbs or back); pain relief by
inhaled methoxyflurane will be equivalent to IM tramadol, as assessed by Visual Analogue
Scale (VAS) at 5, 10, 15 and 20 min after start of the study treatments.
Introduction
Current practice in Singapore Emergency Ambulance Service (EAS) includes the use of
analgesia delivered via inhalation Enthanox (Nitrous Oxide). However there are difficulties
administering Enthanox on-scene due to the added weight of carrying bulky cylinder tanks. It
is common for a delay in administration of analgesia. In addition, there are problems with
storage, leakage, maintenance and occupational exposure of the EAS crew members. Therefore,
there is a need for better standard of care treatment.
Inhaled methoxyflurane (Penthrox) is a potential agent for early administration of analgesia
by EAS. It is extensively used in the pre-hospital setting in Australia. However data on its
use as an analgesic agent in general are limited and there are few published controlled
trials of methoxyflurane in an analgesic role. Intramuscular (IM) tramadol is a common
medication used in the hospital setting for analgesia. It is well proven, simple to deliver
and is not a controlled drug. We intend to conduct a clinical evaluation trial comparing the
use of inhaled Penthrox with IM Tramadol for early pain relief.
Objective & Hypothesis
Primary objectives:
To compare Penthrox (methoxyflurane) and Tramadol in the treatment of acute pain in patients
transported by the Singapore Civil Defense Force (SCDF) EAS with respect to:
- Pain Score assessed by Visual Analogue Scale (VAS) at 5,10, 15 and 20 min after start
of the study treatment
- Time arrived at scene to delivery of first analgesia
- Time to onset of analgesia (arrive at scene to ≥ 3 point reduction in pain score
assessed by VAS)
Secondary Objective:
- To understand patients' perception of pain, satisfaction in pain management, and the
use of the analgesic inhaler compared with IM tramadol in the treatment of acute pain.
- To understand staff satisfaction with pain management, and the ease of use of the
analgesic inhaler compared with IM tramadol in the treatment of acute pain.
- To assess Ramsay sedation scores at 5, 10, 15 and 20 min after start of the study
treatment
- Vital signs (i.e. Respiratory rate, heart rate, blood pressure and GCS)
Methods Study Design
A phased, prospective, non-randomised, before-after evaluation study comparing Penthrox
(Methoxyflurane) and Tramadol in patients with acute pain managed by SCDF EAS.
The trial will recruit 400 eligible patients over 1 year (200 Penthrox and 200 tramadol).
200 samples of Penthrox will be provided free of charge by Medical Developments
International (MDI), an Australian company, for evaluation during the trial. Patients
managed by SCDF EAS for treatment of acute pain and who meet the eligibility criteria will
be recruited into the study. Intramuscular tramadol will be purchased by SCDF for this
implementation trial.
Half of SCDF's 30 ambulances (15 ambulances), will be randomly assigned, equipped and
trained to carry the new medication (Penthrox). The other half (15 ambulances), will be
trained and equipped with IM tramadol. Allocation will be on a per station level. After 6
months, the two separate cohort of ambulances will cross over to administer Penthrox and
Tramadol and respectively. This is done in order to minimize any potential patient selection
bias and ambulance crew operator bias arising in the two 6-monthly time periods.
All paramedics will be trained to use both medications, the pain scales and Ramsey scores,
and will record patient's pain, sedation scores patient and staff satisfaction as part of
routine clinical practice. In the case when one or both study drugs are used up before the
cross-over period, or the patient is ineligible for either drug, SCDF ambulances will still
carry Enthanox as a back up analgesia.
SGH will be submitting an ethics application to Centralised Institutional Review Board
(CIRB) on behalf of SCDF to recruit all cases presenting to SCDF, irrespective of
destination hospital. This is because SCDF does not have its own IRB. All patients will be
followed up by a review of their Emergency Department and hospital records for any
medication related adverse effects.
Enrollment of Patients Patients will be given the treatment if all eligibility criteria are
met and treatment is indicated by protocol. For patients who do not meet inclusion and
exclusion criteria for either of the new treatments, Enthanox will still be kept on
ambulances during the study period for back up analgesia. No written consent will be sought
as this will be part of routine clinical care.
Team members Contribution SCDF staff members will be enrolling eligible participants and
administer the study drugs. The SGH study team will provide clinical input into protocols,
physician oversight, training for paramedics, data quality control, analysis of data and
interpretation of results etc.
Quality Assurance
This study will include the following specific elements for quality assurance:
- Development of standard protocols to perform all data collection and follow-up
activities
- Development and adherence to a detailed Standard Operation Procedures (SOP)
- Use of standardized forms and uniform criteria for patient recruitment
- Standardized data processing, editing and generation of edit statements
- Regular communications between the study investigators to resolve questions
- Internal and external monitoring of data collection
Additional steps to ensure data quality include: range checks and verification built into
the data entry system and a sequence of logic checking and examination of variables.
Human Subjects Instructions
Risk Reduction
- A formal education and training program will be conducted for all paramedics who will be
administering both treatments to patients. This will include didactic and practical training
sessions, and competency certification before they will be allow to administer the
treatment. Paramedics will also be taught how to monitor patients, watch for adverse effects
and how to treat them.
A formal education and training program will be conducted for all investigators who will be
conducting surveys to reduce the risks regarding confidentiality. All subjects' identifiers
will be removed from the database to protect subjects' confidentiality.
Risk/Benefit
- Comparison of Penthrox and Tramadol will help to advise which drug can be used as a
standard drug in the EAS for treatment of acute pain patients. This study has the
potential to change practice in Singapore and beyond, and allow patients earlier relief
of pain and suffering.
Compensation Plan - No compensation will be provided to the patients or any family members.
Informed Consent Issues
- Apply for waiver of consent for this study. Only collecting patients' pain scale
information from SCDF EAS. Therefore, it poses no additional risks to the patients. All
patient identifiers will be subsequently removed from the dataset.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04484610 -
Appropriate Opioid Quantities for Acute Pain - Pharmacist Study
|
Phase 4 | |
Recruiting |
NCT05054179 -
Pecto-Intercostal Fascial Plane Block Catheter Trial for Reduction of Sternal Pain
|
Phase 2/Phase 3 | |
Completed |
NCT04548635 -
VR for Burn Dressing Changes at Home
|
Phase 2/Phase 3 | |
Recruiting |
NCT05370404 -
Prescribing vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients With Postoperative Pain:
|
N/A | |
Completed |
NCT06054945 -
Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
|
||
Completed |
NCT03825549 -
A Randomized Trial of Behavioral Economic Approaches to Reduce Unnecessary Opioid Prescribing
|
N/A | |
Completed |
NCT05995912 -
Efficacy and Safety of Etoricoxib-tramadol Tablet in Acute Postoperative Pain
|
Phase 2 | |
Recruiting |
NCT05589246 -
Regional Analgesia in Combination With Cryoanalgesia to Prevent Acute Pain Following Nuss Procedure
|
N/A | |
Recruiting |
NCT05572190 -
Evaluate the Safety and Pharmacokinetic Profile of ETR028 and ETR029 in Healthy Adult Subjects
|
Phase 1 | |
Terminated |
NCT04716413 -
Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment
|
Phase 4 | |
Active, not recruiting |
NCT03537573 -
Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care
|
N/A | |
Not yet recruiting |
NCT06317844 -
Examination of Psychological and Physiological Pathways Linking Gratitude and Pain
|
N/A | |
Withdrawn |
NCT02957097 -
Gabapentin as a Pre-emptive Analgesic in Oral and Maxillofacial Surgical Procedures
|
Phase 4 | |
Completed |
NCT02565342 -
Interscalene Brachial Plexus Block to Treat Pain After Clavicular Surgery
|
Phase 4 | |
Terminated |
NCT02599870 -
Clinical Study to Evaluate Clinical Impact of PGx-Guided Treatment for Patients Undergoing Elective Spinal Surgical Procedures
|
N/A | |
Completed |
NCT02380989 -
Integrative Ayurveda Healing Relieves Minor Sports Injury Pain
|
Phase 2 | |
Completed |
NCT02984098 -
40% Orally Administered Dextrose Gel is More Effective Than 25% Dextrose
|
Phase 4 | |
Completed |
NCT02489630 -
Low Dose Ketamine as an Adjunct to Opiates for Acute Pain in the Emergency Department
|
Phase 4 | |
Completed |
NCT03107338 -
Preventive Treatment of Pain After Dental Implant Surgery
|
Phase 4 | |
Completed |
NCT02817477 -
Intranasal Ketamine for Acute Traumatic Pain
|
Phase 4 |